ALKERMES PLC (ALKS) Stock Fundamental Analysis

NASDAQ:ALKS • IE00B56GVS15

33.29 USD
-1.62 (-4.64%)
At close: Feb 12, 2026
33.4727 USD
+0.18 (+0.55%)
After Hours: 2/12/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

Overall ALKS gets a fundamental rating of 6 out of 10. We evaluated ALKS against 523 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making ALKS a very profitable company, without any liquidiy or solvency issues. ALKS is not valued too expensively and it also shows a decent growth rate. These ratings would make ALKS suitable for quality investing!


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • ALKS had positive earnings in the past year.
  • ALKS had a positive operating cash flow in the past year.
  • In multiple years ALKS reported negative net income over the last 5 years.
  • In the past 5 years ALKS always reported a positive cash flow from operatings.
ALKS Yearly Net Income VS EBIT VS OCF VS FCFALKS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

  • ALKS's Return On Assets of 14.57% is amongst the best of the industry. ALKS outperforms 95.22% of its industry peers.
  • With an excellent Return On Equity value of 19.58%, ALKS belongs to the best of the industry, outperforming 95.79% of the companies in the same industry.
  • ALKS has a Return On Invested Capital of 16.22%. This is amongst the best in the industry. ALKS outperforms 96.37% of its industry peers.
Industry RankSector Rank
ROA 14.57%
ROE 19.58%
ROIC 16.22%
ROA(3y)8.82%
ROA(5y)3.68%
ROE(3y)13.16%
ROE(5y)4.95%
ROIC(3y)N/A
ROIC(5y)N/A
ALKS Yearly ROA, ROE, ROICALKS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

1.3 Margins

  • Looking at the Profit Margin, with a value of 22.30%, ALKS belongs to the top of the industry, outperforming 94.46% of the companies in the same industry.
  • Looking at the Operating Margin, with a value of 23.59%, ALKS belongs to the top of the industry, outperforming 95.60% of the companies in the same industry.
  • ALKS has a Gross Margin of 86.04%. This is amongst the best in the industry. ALKS outperforms 88.72% of its industry peers.
  • In the last couple of years the Gross Margin of ALKS has remained more or less at the same level.
Industry RankSector Rank
OM 23.59%
PM (TTM) 22.3%
GM 86.04%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.43%
GM growth 5Y-0.08%
ALKS Yearly Profit, Operating, Gross MarginsALKS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), ALKS is creating value.
  • The number of shares outstanding for ALKS has been reduced compared to 1 year ago.
  • The number of shares outstanding for ALKS has been increased compared to 5 years ago.
  • ALKS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ALKS Yearly Shares OutstandingALKS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ALKS Yearly Total Debt VS Total AssetsALKS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • ALKS has an Altman-Z score of 6.88. This indicates that ALKS is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 6.88, ALKS is in the better half of the industry, outperforming 76.67% of the companies in the same industry.
  • ALKS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 6.88
ROIC/WACC2.08
WACC7.8%
ALKS Yearly LT Debt VS Equity VS FCFALKS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

  • ALKS has a Current Ratio of 3.67. This indicates that ALKS is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 3.67, ALKS is in line with its industry, outperforming 44.55% of the companies in the same industry.
  • A Quick Ratio of 3.27 indicates that ALKS has no problem at all paying its short term obligations.
  • ALKS has a Quick ratio (3.27) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.67
Quick Ratio 3.27
ALKS Yearly Current Assets VS Current LiabilitesALKS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • ALKS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.71%, which is quite good.
  • ALKS shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 32.50% yearly.
  • Looking at the last year, ALKS shows a small growth in Revenue. The Revenue has grown by 1.08% in the last year.
  • Measured over the past years, ALKS shows a small growth in Revenue. The Revenue has been growing by 5.87% on average per year.
EPS 1Y (TTM)19.71%
EPS 3Y54.92%
EPS 5Y32.5%
EPS Q2Q%-31.94%
Revenue 1Y (TTM)1.08%
Revenue growth 3Y9.89%
Revenue growth 5Y5.87%
Sales Q2Q%4.24%

3.2 Future

  • Based on estimates for the next years, ALKS will show a small growth in Earnings Per Share. The EPS will grow by 4.24% on average per year.
  • The Revenue is expected to grow by 7.98% on average over the next years.
EPS Next Y-48.45%
EPS Next 2Y-28.14%
EPS Next 3Y-18.85%
EPS Next 5Y4.24%
Revenue Next Year-2.41%
Revenue Next 2Y9.66%
Revenue Next 3Y7.48%
Revenue Next 5Y7.98%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALKS Yearly Revenue VS EstimatesALKS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B
ALKS Yearly EPS VS EstimatesALKS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 13.42 indicates a correct valuation of ALKS.
  • Compared to the rest of the industry, the Price/Earnings ratio of ALKS indicates a rather cheap valuation: ALKS is cheaper than 96.94% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.67. ALKS is valued rather cheaply when compared to this.
  • Based on the Price/Forward Earnings ratio of 22.23, the valuation of ALKS can be described as rather expensive.
  • 93.12% of the companies in the same industry are more expensive than ALKS, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 27.69. ALKS is around the same levels.
Industry RankSector Rank
PE 13.42
Fwd PE 22.23
ALKS Price Earnings VS Forward Price EarningsALKS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ALKS is valued cheaply inside the industry as 97.32% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of ALKS indicates a rather cheap valuation: ALKS is cheaper than 98.28% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 11.19
EV/EBITDA 10
ALKS Per share dataALKS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

  • The decent profitability rating of ALKS may justify a higher PE ratio.
  • A cheap valuation may be justified as ALKS's earnings are expected to decrease with -18.86% in the coming years.
PEG (NY)N/A
PEG (5Y)0.41
EPS Next 2Y-28.14%
EPS Next 3Y-18.85%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ALKS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALKERMES PLC

NASDAQ:ALKS (2/12/2026, 8:00:00 PM)

After market: 33.4727 +0.18 (+0.55%)

33.29

-1.62 (-4.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12
Earnings (Next)04-29
Inst Owners105.82%
Inst Owner Change-1.38%
Ins Owners1.48%
Ins Owner Change4.25%
Market Cap5.50B
Revenue(TTM)1.52B
Net Income(TTM)339.32M
Analysts80.87
Price Target44.69 (34.24%)
Short Float %13.38%
Short Ratio11.25
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)66.1%
Min EPS beat(2)59.84%
Max EPS beat(2)72.36%
EPS beat(4)4
Avg EPS beat(4)43.68%
Min EPS beat(4)12.02%
Max EPS beat(4)72.36%
EPS beat(8)4
Avg EPS beat(8)10.27%
EPS beat(12)8
Avg EPS beat(12)42.89%
EPS beat(16)11
Avg EPS beat(16)151.46%
Revenue beat(2)2
Avg Revenue beat(2)10.32%
Min Revenue beat(2)8.51%
Max Revenue beat(2)12.13%
Revenue beat(4)3
Avg Revenue beat(4)7.62%
Min Revenue beat(4)-1.19%
Max Revenue beat(4)12.13%
Revenue beat(8)4
Avg Revenue beat(8)3.11%
Revenue beat(12)7
Avg Revenue beat(12)3.8%
Revenue beat(16)10
Avg Revenue beat(16)3.09%
PT rev (1m)-0.14%
PT rev (3m)0.18%
EPS NQ rev (1m)-3.14%
EPS NQ rev (3m)-3.13%
EPS NY rev (1m)-0.79%
EPS NY rev (3m)-0.83%
Revenue NQ rev (1m)0.48%
Revenue NQ rev (3m)0.66%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.2%
Valuation
Industry RankSector Rank
PE 13.42
Fwd PE 22.23
P/S 3.61
P/FCF 11.19
P/OCF 10.17
P/B 3.17
P/tB 3.33
EV/EBITDA 10
EPS(TTM)2.48
EY7.45%
EPS(NY)1.5
Fwd EY4.5%
FCF(TTM)2.98
FCFY8.94%
OCF(TTM)3.27
OCFY9.84%
SpS9.21
BVpS10.5
TBVpS9.99
PEG (NY)N/A
PEG (5Y)0.41
Graham Number24.2
Profitability
Industry RankSector Rank
ROA 14.57%
ROE 19.58%
ROCE 19.34%
ROIC 16.22%
ROICexc 40.45%
ROICexgc 45.58%
OM 23.59%
PM (TTM) 22.3%
GM 86.04%
FCFM 32.29%
ROA(3y)8.82%
ROA(5y)3.68%
ROE(3y)13.16%
ROE(5y)4.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.43%
GM growth 5Y-0.08%
F-Score6
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 163.07%
Cap/Sales 3.25%
Interest Coverage 250
Cash Conversion 138.93%
Profit Quality 144.77%
Current Ratio 3.67
Quick Ratio 3.27
Altman-Z 6.88
F-Score6
WACC7.8%
ROIC/WACC2.08
Cap/Depr(3y)76.88%
Cap/Depr(5y)63.55%
Cap/Sales(3y)2.83%
Cap/Sales(5y)2.99%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.71%
EPS 3Y54.92%
EPS 5Y32.5%
EPS Q2Q%-31.94%
EPS Next Y-48.45%
EPS Next 2Y-28.14%
EPS Next 3Y-18.85%
EPS Next 5Y4.24%
Revenue 1Y (TTM)1.08%
Revenue growth 3Y9.89%
Revenue growth 5Y5.87%
Sales Q2Q%4.24%
Revenue Next Year-2.41%
Revenue Next 2Y9.66%
Revenue Next 3Y7.48%
Revenue Next 5Y7.98%
EBIT growth 1Y-17.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2.93%
EBIT Next 3Y5.58%
EBIT Next 5Y12.64%
FCF growth 1Y93.4%
FCF growth 3Y76.56%
FCF growth 5YN/A
OCF growth 1Y83.22%
OCF growth 3Y62.84%
OCF growth 5Y43.53%

ALKERMES PLC / ALKS FAQ

What is the fundamental rating for ALKS stock?

ChartMill assigns a fundamental rating of 6 / 10 to ALKS.


What is the valuation status of ALKERMES PLC (ALKS) stock?

ChartMill assigns a valuation rating of 6 / 10 to ALKERMES PLC (ALKS). This can be considered as Fairly Valued.


Can you provide the profitability details for ALKERMES PLC?

ALKERMES PLC (ALKS) has a profitability rating of 7 / 10.


Can you provide the expected EPS growth for ALKS stock?

The Earnings per Share (EPS) of ALKERMES PLC (ALKS) is expected to decline by -48.45% in the next year.